-
Product Insights
IgA Nephropathy (Berger's Disease): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “IgA Nephropathy (Berger's Disease) - Global Clinical Trials Review, 2025" provides an overview of IgA Nephropathy (Berger's Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on IgA Nephropathy (Berger's Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Malnutrition: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Malnutrition - Global Clinical Trials Review, 2025" provides an overview of Malnutrition Clinical trials scenario. This report provides top line data relating to the clinical trials on Malnutrition. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Lupus Nephritis: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Lupus Nephritis - Global Clinical Trials Review, 2025" provides an overview of Lupus Nephritis Clinical trials scenario. This report provides top line data relating to the clinical trials on Lupus Nephritis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Monkeypox: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Monkeypox - Global Clinical Trials Review, 2025" provides an overview of Monkeypox Clinical trials scenario. This report provides top line data relating to the clinical trials on Monkeypox. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Cytopenia: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Cytopenia - Global Clinical Trials Review, 2025" provides an overview of Cytopenia Clinical trials scenario. This report provides top line data relating to the clinical trials on Cytopenia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Hypoglycemia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hypoglycemia Therapeutics. • In 2024 and 2029, India is estimated to have the highest number of diagnosed incident cases of hypoglycemia, representing a large portion of global cases. • Novo Nordisk’s GlucaGen (glucagon hypokit) and Eli Lilly’s Glucagon had been the primary marketed glucagons for decades. • The hypoglycemia pipeline holds 16 molecules, with no assets in the pre-registration stage, three assets in Phase III development,...
-
Thematic Analysis
Genome Editing Drugs Landscape: Comprehensive Analysis of Current Drugs and Dynamics
The Genome Editing Drugs Landscape report delivers a comprehensive analysis of the current and emerging genome editing therapies shaping the pharmaceutical industry. Viewed through the lens of drug development, clinical progress, regulatory evolution, and commercial performance, the report helps stakeholders understand how genome editing technologies are transitioning from experimental platforms to viable therapeutic solutions. By combining clinical pipeline analysis, regulatory developments, and market performance insights, the report highlights the key forces reshaping the genome editing landscape. It enables readers to...
-
Sector Analysis
IDWeek 2025: Pre-Conference Coverage
IDWeek is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists. In advance of the confernece, GlobalData highlighted highly anticipated and noteworthy abstracts in this Pre-Conference Coverage report.
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, September 2025
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
Diabetic Retinopathy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Diabetic Retinopathy Therapeutics. • In 2024, there were more than 46 million ldiagnosed prevalent cases of DR in the 16 countries covered in GlobalData’s epidemiology forecast. • Currently, the DR market is saturated with generic drugs, and the platelet activating factor (PAF) inhibitor drug class dominates the approved innovator drugs currently available to treat DR. • The DR pipeline holds 140 molecules, with three assets in...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.